公开(公告)号：WO9820836A2

公开(公告)日：1998-05-22

申请号：PCT/US9721829

申请日：1997-11-13

Applicant: PATHOGENESIS CORP

Inventor： VANDEVANTER DONALD R ,  MONTGOMERY ALAN B

IPC: A61K9/12 ,  A61K9/00 ,  A61K38/00 ,  A61K38/12 ,  A61P11/00 ,  A61P31/04 ,  C07K7/50 ,  C07K7/62 ,  A61K

CPC classification number: A61K9/0078 ,  A61K38/12 ,  C07K7/62

Abstract: An anti-Pseudomonas aeruginosa agent which is substantially pure biologically active colistin component, a mixture thereof or a pharmaceutically acceptable salt thereof delivered as an aerosol or dry powder formulation. A formulation and method for preparation of substantially pure biologically active colistin, its components, mixtures thereof and a pharmaceutically acceptable salts thereof. A method for treatment and prophylaxis of Pseudomonas aeruginosa, Stenotrophomonas maltophilia or other susceptible pulmonary bacterial infections.

Abstract translation: 作为气溶胶或干粉制剂递送的基本上纯的生物活性粘菌素组分，其混合物或其药学上可接受的盐的抗绿脓假单胞菌试剂。 用于制备基本上纯的生物活性粘菌素，其组分，其混合物及其药学上可接受的盐的制剂和方法。 一种治疗和预防铜绿假单胞菌，嗜麦芽寡养单胞菌或其他易感性肺细菌感染的方法。

公开(公告)号：WO0035408A3

公开(公告)日：2000-11-02

申请号：PCT/US9930101

申请日：1999-12-16

Applicant: PATHOGENESIS CORP

Inventor： ROSE LYNN M ,  PORUBEK DAVID J ,  MONTGOMERY ALAN B

IPC: C07D498/18 ,  A61K9/02 ,  A61K9/14 ,  A61K9/20 ,  A61K9/50 ,  A61K9/52 ,  A61K31/00 ,  A61K31/133 ,  A61K31/42 ,  A61K31/4409 ,  A61K31/4965 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/70 ,  A61K31/7036 ,  A61K31/7048 ,  A61K31/7052 ,  A61K38/00 ,  A61P1/04 ,  A61P11/00 ,  A61P31/04 ,  A61P31/06 ,  A61P31/18 ,  A01N43/40 ,  A61K31/44

CPC classification number: A61K31/538 ,  A61K31/00 ,  A61K31/70 ,  C10M101/025 ,  C10M103/06 ,  C10M105/14 ,  C10M105/24 ,  C10M107/34 ,  C10M107/36 ,  C10M111/00 ,  C10M2201/0603 ,  C10M2201/0613 ,  C10M2201/0623 ,  C10M2201/0653 ,  C10M2201/0663 ,  C10M2201/0803 ,  C10M2201/0853 ,  C10M2201/0863 ,  C10M2201/0873 ,  C10M2201/1006 ,  C10M2201/1023 ,  C10M2201/1033 ,  C10M2201/1053 ,  C10M2201/123 ,  C10M2205/143 ,  C10M2205/163 ,  C10M2205/173 ,  C10M2205/183 ,  C10M2207/0225 ,  C10M2207/1203 ,  C10M2207/1213 ,  C10M2207/1253 ,  C10M2207/163 ,  C10M2207/183 ,  C10M2207/203 ,  C10M2207/243 ,  C10M2209/1033 ,  C10M2209/1045 ,  C10M2209/1055 ,  C10M2209/1065 ,  C10M2209/1075 ,  C10M2209/1085 ,  C10M2209/1095 ,  C10M2209/123 ,  Y10S514/924 ,  Y10S514/931 ,  A61K2300/00

Abstract: A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

Abstract translation: 利福拉齐治疗细菌感染的方法，每周一次或每周两次。 一种治疗由结核分枝杆菌引起的肺结核，由鸟分枝杆菌复合物引起的感染，由肺炎衣原体引起的感染和由幽门螺杆菌引起的感染的方法，通过给患有细菌感染的患者施用1-100mg利福拉齐每周一次或两次 。 在该剂量方案中，治疗速度快，有效且消除了每日剂量1-50mg利福拉齐所观察到的不良继发症状。

公开(公告)号：JP2007302698A

公开(公告)日：2007-11-22

申请号：JP2007213191

申请日：2007-08-17

Applicant: Pathogenesis Corp ,  パソジェネシス コーポレイション

Inventor： VANDEVANTER DONALD R ,  MONTGOMERY ALAN B

IPC: A61K9/12 ,  A61K38/00 ,  A61K9/00 ,  A61K9/72 ,  A61K38/12 ,  A61P11/00 ,  A61P31/04 ,  C07K7/50 ,  C07K7/62

CPC classification number: A61K9/0078 ,  A61K38/12 ,  C07K7/62

Abstract: PROBLEM TO BE SOLVED: To provide a pure biologically active colistin, its component, and a colistin formulation for the treatment of pulmonary infection. SOLUTION: The pure biologically active colistin, all its components, a given mixture thereof or a pharmaceutically acceptable salt thereof and an aerosol formulation containing the substantially pure biologically active colistin, any of its biologically active components, a mixture thereof or a pharmaceutically acceptable salt thereof are provided. The formulation is suitable for atomization, and an atomized form offers an effective treatment and prevention of Pseudomonas aeruginosa infection or other susceptible pulmonary infections (e.g. Stenotrophomonas maltophilia). COPYRIGHT: (C)2008,JPO&INPIT

Abstract translation: 要解决的问题：提供纯生物活性的粘菌素，其组分和用于治疗肺部感染的粘菌素制剂。 解决方案：纯生物活性粘菌素，其所有组分，给定的混合物或其药学上可接受的盐和含有基本上纯的生物活性粘菌素，其任何生物活性成分，其混合物或药学上可接受的盐 提供其可接受的盐。 该制剂适用于雾化，并且雾化形式提供铜绿假单胞菌感染或其他敏感性肺部感染（例如嗜麦芽寡养单胞菌（Stenotrophomonas maltophilia））的有效治疗和预防。 版权所有（C）2008，JPO＆INPIT

公开(公告)号：EP0848721A4

公开(公告)日：2000-12-27

申请号：EP96929937

申请日：1996-09-06

Applicant: PATHOGENESIS CORP

Inventor： BAKER WILLIAM R ,  TOWELL J ANDREW ,  HARNESS JAMES R

IPC: C12N15/09 ,  B01J19/00 ,  B01L3/00 ,  B01L7/00 ,  C08F2/00 ,  C12M1/00 ,  C40B60/14

CPC classification number: B01L3/50851 ,  B01J19/0046 ,  B01J2219/00283 ,  B01J2219/00308 ,  B01J2219/0031 ,  B01J2219/00335 ,  B01J2219/00373 ,  B01J2219/00484 ,  B01J2219/00495 ,  B01J2219/00585 ,  B01J2219/0059 ,  B01L3/50853 ,  B01L7/52 ,  C40B60/14

Abstract: A method and device (2) for the simultaneous production of chemical compounds in an array which is capable of providing a very broad range of reaction environments including reaction temperatures of -40 °C to 150 °C, reflux condensation, and a selective gas environment. The invention also allows the addition of several reagents (4) during the course of the production process. The device (2) is comprised of a number of different block sections (6, 24, 18) which are fastened together to provide the required reaction environment.

公开(公告)号：EP0784700A4

公开(公告)日：1999-09-01

申请号：EP95935267

申请日：1995-10-02

Applicant: PATHOGENESIS CORP

Inventor： STOVER KENDALL ,  HICKEY MARK JEFFREY

IPC: C12N9/02 ,  C12N15/74 ,  C12Q1/02 ,  C12Q1/68 ,  C12Q1/66 ,  C12N1/20

CPC classification number: C12N9/0069 ,  C12N15/74 ,  C12Q1/02 ,  C12Q1/6897

公开(公告)号：EP0734249A4

公开(公告)日：1997-09-10

申请号：EP95937397

申请日：1995-10-17

Applicant: PATHOGENESIS CORP ,  CHILDRENS HOSP MEDICAL CENTER

Inventor： SMITH ARNOLD L ,  RAMSEY BONNIE W ,  MONTGOMERY ALAN B

IPC: A61K9/12 ,  A61K9/00 ,  A61K9/72 ,  A61K31/702 ,  A61K31/715 ,  A61P31/04 ,  A61K31/73

CPC classification number: A61K9/0078 ,  A61K31/7036 ,  Y10S514/956

Abstract: An aminoglycoside formulation for delivery by aerosolization. The concentrated aminoglycoside formulation containing an efficacious amount of aminoglycoside able to inhibit 95-100 % of susceptible bacteria. Aminoglycoside is formulated in 5 ml solution of a quater normal saline having pH between 5.5 and 6.5. The method for treatment of endobronchial infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 mu , produced by a jet or ultrasonic nebulizer.

公开(公告)号：PL348812A1

公开(公告)日：2002-06-17

申请号：PL34881299

申请日：1999-12-17

Applicant: PATHOGENESIS CORP

Inventor： MONTGOMERY ALAN B ,  BAKER WILLIAM R

IPC: A61K20060101 ,  A61K9/00 ,  A61K9/12 ,  A61K9/14 ,  A61K9/72 ,  A61K31/70 ,  A61K31/7036 ,  A61M11/00 ,  A61M13/00 ,  A61P11/00 ,  A61P11/08 ,  A61P31/04

Abstract: The present invention is directed to a method for the treatment of severe chronic bronchitis, i.e., bronchiectasis, using a concentrated aminoglycoside antibiotic formulation delivering the antibiotic to the lung endobronchial space, including alveoli, in an aerosol or dry powder having a mass medium diameter predominately between 1 to 5 microns.

公开(公告)号：AU730546B2

公开(公告)日：2001-03-08

申请号：AU5790998

申请日：1997-11-13

Applicant: PATHOGENESIS CORP

Inventor： VANDEVANTER DONALD R ,  MONTGOMERY ALAN B

IPC: A61K9/12 ,  A61K9/00 ,  A61K38/00 ,  A61K38/12 ,  A61P11/00 ,  A61P31/04 ,  C07K7/50 ,  C07K7/62 ,  A61K31/00

公开(公告)号：CA2179305C

公开(公告)日：2000-10-31

申请号：CA2179305

申请日：1995-10-17

Applicant: PATHOGENESIS CORP ,  CHILDREN S HOSPITAL & MEDICAL

Inventor： SMITH ARNOLD L ,  RAMSEY BONNIE W ,  MONTGOMERY ALAN B

IPC: A61K9/12 ,  A61K9/00 ,  A61K9/72 ,  A61K31/702 ,  A61K31/715 ,  A61P31/04 ,  A61K31/73

Abstract: An aminoglycoside formulation for delivery by aerosolization. The concentrated aminoglycoside formulation containing an efficacious amount of aminoglycoside able to inhibit 95-100 % of susceptible bacteria. Aminoglycoside is formulated in 5 ml solution of a quater normal saline having pH between 5.5 and 6.5. The method for treatment of endobronchial infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 .mu., produced by a jet or ultrasonic nebulizer.

公开(公告)号：GR3031770T3

公开(公告)日：2000-02-29

申请号：GR990402861

申请日：1999-11-05

Applicant: PATHOGENESIS CORP ,  CHILDRENS HOSP MEDICAL CENTER

Inventor： SMITH ARNOLD L ,  RAMSEY BONNIE W ,  MONTGOMERY ALAN B

IPC: A61K9/12 ,  A61K9/00 ,  A61K9/72 ,  A61K31/702 ,  A61K31/715 ,  A61P31/04 ,  A61K31/73

Abstract: An aminoglycoside formulation for delivery by aerosolization. The concentrated aminoglycoside formulation containing an efficacious amount of aminoglycoside able to inhibit 95-100% of susceptible bacteria. Aminoglycoside formulated in 5 ml solution of a quarter normal saline having pH between 5.5 and 6.5. The method for treatment of endobronchial infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 mu , produced by a jet or ultrasonic nebulizer.